hotspot -WSS

hotspot

author：comprehensive 2025-09-09 05:35:26 - browse：331

Photo illustration with orange background of Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) -- biotech coverage from STAT — Desmond Padhi, PharmD, interim CEO, Latigo (center), with Latigo board chair Nancy Stagliano (left) and Westlake Village BioPartners founding managing director Sean Harper, M.D. (right) Illustration: Christine Kao/STAT; Courtesy: Steve Shoffner & Michael Haber

After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched Wednesday with $135 million and plans to compete with Vertex Pharmaceuticals.

The startup is called Latigo Biotherapeutics, and it’s launching having already started a Phase 1 trial for a non-opioid pain medicine, LTG-001. The oral therapy is designed to silence pain-signaling neurons by blocking a sodium channel called NaV 1.8.

Westlake had set out years ago to scout out new options for pain medicines, and found a research desert, according to founding managing director Sean Harper. But NaV 1.8 has emerged as a promising option because of its potential to be non-addictive and to lessen pain without affecting a person’s central nervous system, digestion, or heart rate, as opioids can. There were still few high-quality molecules in development that could be licensed from an academic lab or another drug company, so Westlake decided to develop its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Listen: Your guide to Wegovy's blockbuster heart study

entertainment

WSS

The history of OxyContin, told through Purdue Pharma documents

5 to watch: Tech startups trying to solve health care's staffing crisis

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Listen: Your guide to Wegovy's blockbuster heart study

Stop the failed accountable care organization experiment

Maui funeral service workers on devastation of fires: 'I'm in shock'

focus

hotspot

knowledge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

After John Oliver segment, STAT readers share their opioid

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Continuity nursing helped my family in our darkest PICU moments

Asbestos, a deadly carcinogen, banned by EPA

Continuity nursing helped my family in our darkest PICU moments

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

How one medical school became remarkably diverse

Genentech weighs delaying cancer therapy after drug pricing law

hotspot

App could help diagnose ear infections more accurately — and at home

Colonoscopy prep: Liquid

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Colonoscopy prep: Liquid

Target recalls 2.2 million additional candles due to laceration, burn hazards

Nurses recount patients attacks

entertainment

entertainment

leisure time

explore